Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score.

7061 Background: Treatment of patients (pts) >60y with AML remains challenging. The MRC and LRF validated a 1y survival risk index score in 2843 older AML pts treated with intensive (IC) and non-intensive (NI) chemotherapy, identifying 3 groups with different risk estimates1. Azacitidine (AZA) prolonged OS in older AML pts vs. conventional care (AZA-AML-001 trial)2. Nevertheless, comparison between AZA and IC was jeopardized by the low number of subjects randomized to AZA or IC. Aim: To assess the impact of AZA in a retrospective cohort of older AML pts, unfit for IC, stratified by the MRC/LRF risk score. Methods: The ALMA cohort accrued 110 unfit AML pts who received compassionate front-line AZA before 2011 in 22 Spanish sites (Ramos F et al, Leuk Res. 2014). Cytogenetic, age, white blood count (WBC), PS and AML type categorized pts as good, standard and poor-risk, as stated by Wheatley’s score. Results: Characteristics of the ALMA cohort and distribution across MRC/LRF risk categories are shown in Table...